Bloomberg Anywhere Login


Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.


Financial Products

Enterprise Products


Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000


Industry Products

Media Services

Follow Us

Last ¥266.00 JPY
Change Today +7.00 / 2.70%
Volume 145.5K
4563 On Other Exchanges
As of 2:00 AM 07/31/15 All times are local (Market data is delayed by at least 15 minutes).

anges mg inc (4563) Snapshot

Previous Close
Day High
Day Low
52 Week High
01/13/15 - ¥438.00
52 Week Low
05/1/15 - ¥224.00
Market Cap
Average Volume 10 Days
Shares Outstanding
Dividend Yield
Current Stock Chart for ANGES MG INC (4563)

Related News

No related news articles were found.

anges mg inc (4563) Related Businessweek News

No Related Businessweek News Found

anges mg inc (4563) Details

AnGes MG, Inc., a biopharmaceutical company, engages in the research and development of genetic medicines and medical devices. It markets Naglazyme, a drug for the treatment of mucopolysaccharidosis. The company is also primarily developing hepatocyte growth factor genetic medicine, Collategene, a gene medicine for the treatment of critical limb ischemia, which is a serious impairment of blood circulation in the legs, is in the last stage of clinical development. Its Collategene is indicated for the treatment of peripheral arterial diseases, ischemic heart diseases, Parkinson’s disease, and lymphedema. In addition, the company also develops NF-kB decoy oligonucleotide that includes atopic dermatitis, disc degeneration, and PTA balloon catheter; and cervical intraepithelial neoplasia and DNA therapeutic vaccines, as well as Allovectin, an immunotherapeutic vaccine. It has strategic alliances with BioLeaders Corporation for the development of CIN therapeutic vaccine; Hosokawa Micron Corporation for the technology development of poly lactic-co-glycolic acid particle preparations containing NF-kB decoy oligonucleotide; Medikit Co., Ltd. for the development and manufacture of percutaneous transluminal angioplasty medical device; Morishita Jintan Co., Ltd. for the research and development of healthcare products using Cure-Peptin; and Vical, Inc. for the development of Allovectin. The company was formerly known as MedGene Bioscience Co., Ltd. and changed its name to AnGes MG, Inc. in October 2001. AnGes MG, Inc. was founded in 1999 and is headquartered in Ibaraki, Japan.

47 Employees
Last Reported Date: 03/30/15
Founded in 1999

anges mg inc (4563) Top Compensated Officers

No compensation data is available at this time for the top officers at this company.

Executives, Board Directors

anges mg inc (4563) Key Developments

AnGes MG, Inc. Obtains Results in Initial Equine Study for Ebola Polyclonal Antibody Therapy Using DNA Vaccine Technology

AnGes MG, Inc. announced that it has obtained positive results in an initial equine study for polyclonal antibodies as a treatment for the E bola virus utilizing gene therapy technology. As announced on January 14, 2015, AnGes initiated the development of therapeutic equine polyclonal antibodies for the Ebola virus using DNA vaccine technology in Japan. Antibodies from horses immunized with the DNA vaccine encoding the Ebola virus glycoprotein antigen will be isolated and purified then developed to treat the Ebola virus in humans. AnGes started an initial study in March 2015 to examine the antibody productions of throroughbred horses injected with the DNA vaccine. The study verified the antibody titers against Ebola glycoprotein in equine serum after injections of the DNA vaccine. The results showed a significant increase in the antibody titers against E bola glycoprotein. Following the results of the initial study, AnGes will prepare a development plan aimed at an early realization of therapeutic equine polyclonal antibodies for the Ebola virus. 2 Equine Polyclonal Antibody Therapy for E bola Virus Using DNA Vaccine Technology The therapeutic equine polyclonal antibodies developed by AnGes utilizes DNA vaccine encoding the Ebola virus glycoprotein antigen. Antibodies from horses immunized with the DNA vaccine will be isolated and purified, then developed to treat the Ebola virus in humans. DNA vaccine technology enables AnGes to produce the polyclonal antibodies quickly and safely, as there will be no need to handle the highly pathogenic virus. AnGes believes the therapeutic equine polyclonal antibodies will be a suitable treatment for the Ebola virus, which requires emergency measures. AnGes has signed an agreement with Vical Incorporated regarding Vical's DNA vaccine technology, for the rights to exclusively develop and commercialize the equine polyclonal antibody therapy in Japan.

AnGes MG, Inc. Reports Unaudited Consolidated Financial Results for the First Quarter Ended March 31, 2015; Provides Earnings Guidance for the Fiscal Year Ending Dec. 31, 2015

AnGes MG, Inc. reported unaudited consolidated financial results for the first quarter ended March 31, 2015. The company's revenue was ¥81 million compared to ¥82 million a year ago. Operating loss was ¥960 million compared to ¥476 million a year ago. Net loss was ¥883 million compared to ¥438 million a year ago. Net loss per share was ¥16.51 compared to ¥14.04 million a year ago. Loss before income taxes and minority interests was ¥880,731 million compared to ¥436,608 million a year ago. For the fiscal year ending Dec. 31, 2015, the company expects revenue of ¥450 million, operating loss of ¥5,800 million, ordinary loss of ¥5,800 million, net loss of ¥5,800 million or ¥108.32 per share.

AnGes MG, Inc. to Report Q1, 2015 Results on Apr 27, 2015

AnGes MG, Inc. announced that they will report Q1, 2015 results on Apr 27, 2015


Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
4563:JP ¥266.00 JPY +7.00

4563 Competitors

Market data is delayed at least 15 minutes.

Company Last Change
No competitor information is available for 4563.
View Industry Companies

Industry Analysis


Industry Average

Valuation 4563 Industry Range
Price/Earnings NM Not Meaningful
Price/Sales 15.2x
Price/Book 2.0x
Price/Cash Flow NM Not Meaningful
TEV/Sales 10.3x

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact ANGES MG INC, please visit Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at